×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ADIL – adial pharmaceuticals, inc (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ADIL
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/3
08:47 am
adil
Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement [Yahoo! Finance]
Low
Report
Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement [Yahoo! Finance]
3/3
08:17 am
adil
Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement
High
Report
Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement
2/24
09:00 am
adil
Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement
Low
Report
Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement
2/23
08:30 am
adil
Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One
Medium
Report
Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One
2/17
09:08 am
adil
Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
Medium
Report
Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
2/17
09:00 am
adil
Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Medium
Report
Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
2/11
10:58 am
adil
Adial Pharmaceuticals (NASDAQ:ADIL) was given a new $8.00 price target on by analysts at UBS Group AG.
Medium
Report
Adial Pharmaceuticals (NASDAQ:ADIL) was given a new $8.00 price target on by analysts at UBS Group AG.
2/4
09:35 am
adil
Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04
Medium
Report
Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/5
05:03 pm
adil
Form 10-K ADIAL PHARMACEUTICALS, For: Dec 31
Low
Report
Form 10-K ADIAL PHARMACEUTICALS, For: Dec 31
3/3
08:17 am
adil
Form 8-K ADIAL PHARMACEUTICALS, For: Feb 26
Medium
Report
Form 8-K ADIAL PHARMACEUTICALS, For: Feb 26
2/24
09:06 am
adil
Form 8-K ADIAL PHARMACEUTICALS, For: Feb 23
Medium
Report
Form 8-K ADIAL PHARMACEUTICALS, For: Feb 23
2/18
11:07 am
adil
Form SCHEDULE 13G ADIAL PHARMACEUTICALS, Filed by: ARMISTICE CAPITAL, LLC
Low
Report
Form SCHEDULE 13G ADIAL PHARMACEUTICALS, Filed by: ARMISTICE CAPITAL, LLC
2/4
04:31 pm
adil
Form 8-K ADIAL PHARMACEUTICALS, For: Feb 03
High
Report
Form 8-K ADIAL PHARMACEUTICALS, For: Feb 03
1/6
04:16 pm
adil
Form 8-K ADIAL PHARMACEUTICALS, For: Jan 05
Medium
Report
Form 8-K ADIAL PHARMACEUTICALS, For: Jan 05
1/6
04:16 pm
adil
Form DEF 14A ADIAL PHARMACEUTICALS, For: Feb 26
Medium
Report
Form DEF 14A ADIAL PHARMACEUTICALS, For: Feb 26
12/23
04:01 pm
adil
Form PRE 14A ADIAL PHARMACEUTICALS, For: Dec 23
Low
Report
Form PRE 14A ADIAL PHARMACEUTICALS, For: Dec 23
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/13
Adial Completes Validation of Genetic Biomarker Test in Collaboration with Eurofins for Upcoming Phase 3 Trial
35.8%
4/16 Adial Pharmaceuticals Verifies Proprietary Genetic Test in Landmark ONWARD(TM) Pivotal Phase 3 Clinical Trial 26.1%
4/22 Form POS AM ADIAL PHARMACEUTICALS, 14.4%
3/26 Adial Pharmaceuticals Receives Issue Notification for Patent Covering AD04 for the Treatment of Opioid Use Disorder 13.0%
12/13 Form 4 ADIAL PHARMACEUTICALS, For: Dec 12 Filed by: Johnson Bankole A. 12.4%
6/6 Adial Pharmaceuticals and Tedor Pharma Announce Collaboration to Manufacture AD04 Through Commercialization 6.8%
3/27 Form 4 ADIAL PHARMACEUTICALS, For: Mar 25 Filed by: Stilley William B. III 6.2%
2/19 Adial Pharmaceuticals Receives Approval to Commence Phase 3 Trial in Bulgaria 6.0%
9/11 Adial Pharmaceuticals Announces Successful Product Retesting of AD04 for Phase 3 Clinical Trial 5.7%
6/13 Adial Pharmaceuticals Receives Notification Prior to Acceptance of Israeli Patent for AD04 in Alcohol Use Disorder 5.6%
4/16 Adial Pharmaceuticals Verifies Proprietary Genetic Test in Landmark ONWARD(TM) Pivotal Phase 3 Clinical Trial 26.1%
4/22 Form POS AM ADIAL PHARMACEUTICALS, 14.4%
3/26 Adial Pharmaceuticals Receives Issue Notification for Patent Covering AD04 for the Treatment of Opioid Use Disorder 13.0%
12/13 Form 4 ADIAL PHARMACEUTICALS, For: Dec 12 Filed by: Johnson Bankole A. 12.4%
6/6 Adial Pharmaceuticals and Tedor Pharma Announce Collaboration to Manufacture AD04 Through Commercialization 6.8%
3/27 Form 4 ADIAL PHARMACEUTICALS, For: Mar 25 Filed by: Stilley William B. III 6.2%
2/19 Adial Pharmaceuticals Receives Approval to Commence Phase 3 Trial in Bulgaria 6.0%
9/11 Adial Pharmaceuticals Announces Successful Product Retesting of AD04 for Phase 3 Clinical Trial 5.7%
6/13 Adial Pharmaceuticals Receives Notification Prior to Acceptance of Israeli Patent for AD04 in Alcohol Use Disorder 5.6%
TOP News Decliners
5/7
Adial Pharmaceuticals Announces Collaboration Agreement with Eurofins for Genetic Biomarker Testing to Support Upcoming Phase 3 Clinical Trial for Alcohol Use Disorder
-13.5%
3/20 Form 10-K ADIAL PHARMACEUTICALS, For: Dec 31 -12.2%
2/14 Adial Pharmaceuticals CEO Selected as a Luncheon Keynote Speaker for the 2020 Wall Street Conference and Retreat -9.8%
3/30 Form 4 ADIAL PHARMACEUTICALS, For: Mar 27 Filed by: Newman James W. Jr. -8.2%
3/5 Form 4 ADIAL PHARMACEUTICALS, For: Mar 03 Filed by: Anderson J. Kermit -8.2%
6/9 Adial Pharmaceuticals Inc (NASDAQ: ADIL) was given a new $5.00 price target on by analysts at Maxim Group. They now have a "buy" rating on the stock. -5.6%
6/19 Adial Pharmaceuticals' Chief Medical Officer Presents AD04 at the Scientific Federation 7th World Congress on Nursing & Healthcare -5.6%
9/5 Adial Pharmaceuticals Completes Key Regulatory Milestone Prior to Commencing European Phase 3 Clinical Trial of AD04 for the Treatment of Alcohol Use Disorder -5.5%
9/11 Adial Pharma up 12% on confirmed product supply for late-stage study [Seeking Alpha] -5.4%
10/29 Adial Completes Final Packaging of AD04 for Shipment to Phase 3 Trial Clinical Sites -5.2%
3/20 Form 10-K ADIAL PHARMACEUTICALS, For: Dec 31 -12.2%
2/14 Adial Pharmaceuticals CEO Selected as a Luncheon Keynote Speaker for the 2020 Wall Street Conference and Retreat -9.8%
3/30 Form 4 ADIAL PHARMACEUTICALS, For: Mar 27 Filed by: Newman James W. Jr. -8.2%
3/5 Form 4 ADIAL PHARMACEUTICALS, For: Mar 03 Filed by: Anderson J. Kermit -8.2%
6/9 Adial Pharmaceuticals Inc (NASDAQ: ADIL) was given a new $5.00 price target on by analysts at Maxim Group. They now have a "buy" rating on the stock. -5.6%
6/19 Adial Pharmaceuticals' Chief Medical Officer Presents AD04 at the Scientific Federation 7th World Congress on Nursing & Healthcare -5.6%
9/5 Adial Pharmaceuticals Completes Key Regulatory Milestone Prior to Commencing European Phase 3 Clinical Trial of AD04 for the Treatment of Alcohol Use Disorder -5.5%
9/11 Adial Pharma up 12% on confirmed product supply for late-stage study [Seeking Alpha] -5.4%
10/29 Adial Completes Final Packaging of AD04 for Shipment to Phase 3 Trial Clinical Sites -5.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: